FDA Approved Drugs for Ophthalmology

FDA Approved Drugs for Ophthalmology

Drugs Approved in 2019

Rocklatan (netarsudil and latanoprost ophthalmic solution); Aerie Pharmaceuticals; For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2019

Drugs Approved in 2018

Oxervate (cenegermin-bkbj) ; Dompe Pharmaceuticals; For the treatment of neurotrophic keratitis, Approved August 2018

Drugs Approved in 2017

Luxturna (voretigene neparvovec); Spark Therapeutics; For the treatment of vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease, Approved December 2017

Rhopressa (netarsudil ophthalmic solution) ; Aerie Pharmaceuticals; For the treatment of glaucoma or ocular hypertension, Approved December 2017

Vyzulta (latanoprostene bunod ophthalmic solution); Bausch & Lomb; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved November 2017

Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017

Drugs Approved in 2016

Humira (adalimumab); Abbvie; For the treatment of uveitis, Approved July 2016

Xiidra (lifitegrast); Shire; For the treatment of dry eye disease, Approved July 2016

Drugs Approved in 2015

Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of diabetic retinopathy of all stages, Approved March 2015

Drugs Approved in 2014

Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of diabetic macular edema, Approved July 2014

Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014

Omidria (phenylephrine and ketorolac injection); Omeros; For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain, Approved June 2014

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014

Drugs Approved in 2012

Cystaran (cysteamine hydrochloride); Sigma Tau Pharmaceuticals; For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012

Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of macular edema following retinal vein occlusion, Approved September 2012

Jetrea (ocriplasmin); Thrombogenics; For the treatment of symptomatic vitreomacular adhesion, Approved October 2012

Lucentis (ranibizumab injection); Genentech; For the treatment of diabetic macular edema, Approved August 2012

Zioptan (tafluprost ophthalmic solution); Merck; For the treatment of elevated intraocular pressure, Approved February 2012

Drugs Approved in 2011

Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011

Drugs Approved in 2010

Xeomin (incobotulinumtoxinA); Merz Pharmaceutical; For the treatment of cervical dystonia and blepharospasm, Approved July 2010

Zymaxid (gatifloxacin ophthalmic solution); Allergan; For the treatment of bacterial conjunctivitis, Approved May 2010

Drugs Approved in 2009

Acuvail (ketorolac tromethamine); Allergan; For the treatment of pain and inflammation following cataract surgery., Approved July 2009

Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals; For the treatment of itching associated with allergic conjunctivitis, Approved September 2009

Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb; For the treatment of bacterial conjunctivitis, Approved June 2009

Ozurdex (dexamethasone); Allergan; For the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion, Approved June 2009

Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics; For the treatment of acute herpetic keratitis, Approved September 2009

Drugs Approved in 2008

Akten (lidocaine hydrochloride); Akorn; For anesthesia during ophthalmologic procedures, Approved October 2008

Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008

Durezol (difluprednate); Sirion Therapeutics; For the treatment of inflammation and pain associated with ocular surgery, Approved June 2008

Drugs Approved in 2007

AzaSite (azithromycin); InSite Vision; For the treatment of bacterial conjunctivitis, Approved April 2007

Drugs Approved in 2006

Lucentis (ranibizumab); Genentech; For the treatment of neovascular (wet) age related macular degeneration, Approved June 2006

Drugs Approved in 2004

Macugen (pegaptanib); Pfizer / Eyetech Pharmaceuticals; For the treatment of wet age-related macular degeneration., Approved December 2004

Drugs Approved in 2002

Restasis (cyclosporine ophthalmic emulsion); Allergan; For the treatment of low tear production., December 2002

Drugs Approved in 2001

Lumigan (bimatoprost ophthalmic solution); Allergan; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001

Travatan (travoprost ophthalmic solution); Alcon; For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001

Valcyte (valganciclovir HCl); Roche; For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001

Drugs Approved in 2000

Betaxon; Alcon; For lowering IOP in patients with chronic open-angle glaucoma or ocular hypertension, Approved February 2000

Quixin (levofloxacin); Santen; For treatment of bacterial conjunctivitis, Approved August 2000

Rescula (unoprostone isopropyl ophthalmic solution) 0.15%; Ciba Vision; For the treatment of open-angle glaucoma or ocular hypertension, Approved August 2000

Visudyne (verteporfin for injection); QLT; For the treatment of wet age-related macular degeneration (wet AMD), Approved April 2000

These drugs are distributed in Richmondhill by:

Dr. Berhooz Azizi

Drugs Approved in 1999

Alamast; Santen; pemirolast potassium ophthalmic solution, Approved September 1999

ZADITOR; Ciba Vision; Treatment for the prevention of itching of the eye, Approved July 1999

Drugs Approved in 1998

Alrex; Bausch & Lomb, Pharmos; Treatment for seasonal allergic conjunctivitis, Approved March 1998

Cosopt; Merck; Treatment for glaucoma or ocular hypertension, Approved April 1998

Lotemax; Bausch & Lomb, Pharmos; Treatment for post-operative eye inflammation, Approved March 1998

Salagen Tablets; MGI Pharma; Treatment for Sjogren’s Syndrome, Approved February 1998

Viroptic; King Pharmaceuticals; Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998

Vitravene Injection; Isis Pharmaceuticals; Treatment for CMV in AIDS patients, Approved August 1998

Drugs Approved in 1997

Acular (ketorolac tromethamine ophthalmic solution) 0.5%; Allergan; Treatment for postoperative inflammation in patients who have undergone cataract extraction, Approved January 1997

Acular (ketorolac tromethamine ophthalmic solution) 0.5%; Allergan; Treatment for post-surgical inflammation following cataract extraction, Approved November 1997

BSS Sterile Irrigating Solution; Alcon; Treatment during ocular surgical procedures, Approved December 1997

Drugs Approved in 1996

AK-Con-A (naphazoline ophthalmic); Akorn; Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use, Approved January 1996

Alphagan (brimonidine); Allergan; Treatment for open-angle glaucoma and ocular hypertension, Approved September 1996

Ocuflox (ofloxacin opthalmic solution) 0.3%; Allergan; Treatment for corneal ulcers, Approved May 1996

OcuHist; Pfizer; Over-the-counter antihistamine eye drop, Approved January 1996

Vistide (cidofovir); Gilead; Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996

Vitrasert Implant; Chiron; Drug delivery system for the treatment of cytomegalovirus, Approved March 199